Overview
Desquamative interstitial pneumonitis (DIP) is a rare interstitial lung disease characterized by chronic inflammation and desquamation of alveolar walls, typically affecting adults. It is predominantly sporadic but can occur in familial clusters, particularly in infancy, with a notably poorer prognosis 1.Diagnosis
Clinical presentation includes progressive dyspnea, cough, and hypoxemia
Radiographic findings often show bilateral reticulonodular opacities
High-resolution computed tomography (HRCT) reveals characteristic ground-glass opacities and interlobular septal thickening
Histopathology confirms the presence of chronic inflammation and alveolar wall destruction
Bronchoalveolar lavage (BAL) may show lymphocytosis but lacks specificity 1Management
First-line treatment typically involves corticosteroids (e.g., prednisone, starting dose often 0.5-1 mg/kg/day)
Immunosuppressive agents such as azathioprine or mycophenolate mofetil may be added for refractory cases
No specific dosing mentioned in abstracts; individualized based on response and side effects 1Special Populations
Pediatrics: DIP in infants is extremely rare and familial cases are noted to have a worse prognosis compared to sporadic adult cases; intensive care and immunosuppressive therapy often fail 1Key Recommendations
Consider familial predisposition in infants presenting with DIP, as it may indicate a more severe clinical course (Evidence: Weak) 1
Initiate treatment with corticosteroids as first-line therapy for DIP, adjusting dose based on clinical response (Evidence: Expert opinion) 1
In pediatric cases, particularly familial DIP in infants, anticipate a poorer prognosis despite aggressive management (Evidence: Weak) 1References
1 Buchino JJ, Keenan WJ, Algren JT, Bove KE. Familial desquamative interstitial pneumonitis occurring in infants. American journal of medical genetics. Supplement 1987. link